We have performed pituitary scintigraphy with 111In-pentreotide (OCT), a
somatostatin analogue, and with metoxybenzamide (
IBZM) by
123I-IBZM in two patients affected by mixed
growth hormone/
prolactin-secreting
pituitary tumors. Short-term
growth hormone (GH) inhibition by a single injection of OCT (100 micrograms s.c.), and short-term
prolactin (PRL) inhibition by
oral administration of 2.5 mg of
bromocriptine (BCR), were also performed in both patients. The first patient, a 26 year old man, showed intense
tumor uptake of
123I-IBZM scintigraphy, whereas 111In-OCT scintigraphy showed moderate
tumor uptake. Five hours after the BCR inhibition test, a fall of 83% in PRL plasma levels (from 8,336 micrograms/L to 1,417 micrograms/L), and of 91.6% in GH plasma levels (from 39.5 micrograms/L to 3.3 micrograms/L) were observed. OCT inhibition test suppressed GH plasma levels from 36 micrograms/L to 3.5 micrograms/L. The patient was submitted to treatment with BCR and OCT. A dramatic shrinkage of the
tumor was seen after six months of
therapy. The lesion disappeared one year after the start of
therapy. The second patient, a 64 year old man, showed intense uptake at 111In-OCT scintigraphy, while
123I-IBZM uptake was not observed. A test dose of BCR resulted in an acute fall of PRL (from 145 micrograms/L to 118 micrograms/L), but not of GH. A test dose of OCT decreased the GH plasma level from 61 micrograms/L to 4.5 micrograms/L. The patient was submitted to treatment with BCR and OCT that resulted in a computed tomography and magnetic resonance imaging decrease of 45% of
tumor volume one year after the start of
therapy. Our results suggest that both suppression tests with OCT and BCR, and scintigraphic studies in vivo with
123I-IBZM and 111In-OCT can be predictive for the effectiveness of
therapies with
dopamine agonists and/or SS-analogs in patients with mixed PRL/GH-secreting
pituitary tumors. Further studies are required to evaluate the role of suppressive tests in selecting patients for appropriate clinical treatments.